Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Apr 15, 2026; 18(4): 113266
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.113266
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.113266
Figure 5 Cost-effectiveness acceptability curves under different willingness-to-pay thresholds.
TACE: Transarterial chemoembolization.
- Citation: Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266
- URL: https://www.wjgnet.com/1948-5204/full/v18/i4/113266.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i4.113266